Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-026751
Filing Date
2020-02-06
Accepted
2020-02-06 16:01:35
Documents
57
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q d879582d10q.htm 10-Q 409371
2 EX-31.1 d879582dex311.htm EX-31.1 10732
3 EX-31.2 d879582dex312.htm EX-31.2 10717
4 EX-32.1 d879582dex321.htm EX-32.1 5692
11 GRAPHIC g879582g59z57.jpg GRAPHIC 101908
  Complete submission text file 0001193125-20-026751.txt   3489041

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT meip-20191231.xml EX-101.INS 616235
6 XBRL TAXONOMY EXTENSION SCHEMA meip-20191231.xsd EX-101.SCH 35640
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE meip-20191231_cal.xml EX-101.CAL 27008
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE meip-20191231_def.xml EX-101.DEF 265336
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE meip-20191231_lab.xml EX-101.LAB 331994
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE meip-20191231_pre.xml EX-101.PRE 293874
Mailing Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130 858-792-6300
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-50484 | Film No.: 20582623
SIC: 2834 Pharmaceutical Preparations